Novartis completes FDA application for 'cancer-killing' technology

Cara Livernois | | Health Exec | Precision Medicine

The race to produce the first CAR-T, a technology capable of reprograming a cancer patient's white blood cells to kill tumor cells, has reached its next phase, thanks to Novartis. In Forbes, Samuele Butera, the Global Business Leader for Cell & Gene Therapies at Novartis, explains the company’s work in fighting cancer within the body.

After announcing the company had completed the application for the use of CAR-T in children with acute lymphoblastic leukemia, the company is currently waiting for a response from the Food and Drug Administration. Novartis’ application comes before that from Kite Pharmaceuticals, who announced its intention to apply in Dec. 2016.

Read the full story by clicking below: 

Novartis Makes Plans For Its Cancer-Killing T Cells

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup